 Connection
Larry Moreland to Clinical Trials as Topic
This is a "connection" page, showing publications Larry Moreland has written about Clinical Trials as Topic.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.453 |
|
|
|
-
Daniel CL, Moreland LW. Infliximab: additional safety data from an open label study. J Rheumatol. 2002 Apr; 29(4):647-9.
Score: 0.124
-
Patel AM, Moreland LW. Certolizumab pegol: a new biologic targeting rheumatoid arthritis. Expert Rev Clin Immunol. 2010 Nov; 6(6):855-66.
Score: 0.056
-
Turkiewicz AM, Moreland LW. Psoriatic arthritis: current concepts on pathogenesis-oriented therapeutic options. Arthritis Rheum. 2007 Apr; 56(4):1051-66.
Score: 0.044
-
Looney RJ, Diamond B, Holers VM, Levesque MC, Moreland L, Nahm MH, St Clair EW. Guidelines for assessing immunocompetency in clinical trials for autoimmune diseases. Clin Immunol. 2007 Jun; 123(3):235-43.
Score: 0.044
-
Misischia RJ, Moreland LW. Rheumatoid arthritis: developing pharmacological therapies. Expert Opin Investig Drugs. 2002 Jul; 11(7):927-35.
Score: 0.032
-
Mikuls T, Moreland L. The treatment of rheumatoid arthritis: a review of recent clinical trials. Curr Rheumatol Rep. 1999 Dec; 1(2):135-8.
Score: 0.026
-
Moreland LW. Inhibitors of tumor necrosis factor for rheumatoid arthritis. J Rheumatol Suppl. 1999 May; 57:7-15.
Score: 0.025
-
Moreland LW. Soluble tumor necrosis factor receptor (p75) fusion protein (ENBREL) as a therapy for rheumatoid arthritis. Rheum Dis Clin North Am. 1998 Aug; 24(3):579-91.
Score: 0.024
-
Moreland LW, Ball GV. Colchicine and gout. Arthritis Rheum. 1991 Jun; 34(6):782-6.
Score: 0.015
-
Austin JS, Ambrose RF, Young PK, Moreland LW, Saway PA, Alarcón GS. Rheumatoid arthritis patients and clinical drug trials. A case-control study. Arthritis Care Res. 1991 Mar; 4(1):22-6.
Score: 0.014
-
Moreland L, Alarcón GS. Comment on the article by Furst et al. Arthritis Rheum. 1989 Dec; 32(12):1631-2.
Score: 0.013
-
Gazi H, Pope JE, Clements P, Medsger TA, Martin RW, Merkel PA, Kahaleh B, Wollheim FA, Baron M, Csuka ME, Emery P, Belch JF, Hayat S, Lally EV, Korn JH, Czirjak L, Herrick A, Voskuyl AE, Bruehlmann P, Inanc M, Furst DE, Black C, Ellman MH, Moreland LW, Rothfield NF, Hsu V, Mayes M, McKown KM, Krieg T, Siebold JR. Outcome measurements in scleroderma: results from a delphi exercise. J Rheumatol. 2007 Mar; 34(3):501-9.
Score: 0.011
-
Russak SM, Croft JD, Furst DE, Hohlbauch A, Liang MH, Moreland L, Ofman JJ, Paulus H, Simon LS, Weisman M, Tugwell P. The use of rheumatoid arthritis health-related quality of life patient questionnaires in clinical practice: lessons learned. Arthritis Rheum. 2003 Aug 15; 49(4):574-84.
Score: 0.009
-
Shanahan JC, Moreland LW, Carter RH. Upcoming biologic agents for the treatment of rheumatic diseases. Curr Opin Rheumatol. 2003 May; 15(3):226-36.
Score: 0.008
-
Clements PJ, Hurwitz EL, Wong WK, Seibold JR, Mayes M, White B, Wigley F, Weisman M, Barr W, Moreland L, Medsger TA, Steen VD, Martin RW, Collier D, Weinstein A, Lally E, Varga J, Weiner SR, Andrews B, Abeles M, Furst DE. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. Arthritis Rheum. 2000 Nov; 43(11):2445-54.
Score: 0.007
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|